Hepatitis c virus biology

Cell Death and Differentiation

Volumn 10, Issue , 2003, Pages S27-S38

  Giannini, C ^a   Brechot C ^a  

^a INSERM   (France)

Author keywords

Apoptosis; Cell signaling; Hcv pathogenesis; Hcv persistence; Hepatitis cvirus; Interferon

Indexed keywords

ANTIVIRUS AGENT; CORE PROTEIN; INTERFERON; RIBAVIRIN; VIRUS PROTEIN; VIRUS RNA;

APOPTOSIS; CELL GROWTH; CELL VIABILITY; ERADICATION THERAPY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LIPID METABOLISM; LIVER CARCINOGENESIS; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; RETROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS; VIRUS TRANSFORMATION;

ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER; SIGNAL TRANSDUCTION; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 17344381535     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401121     Document Type: Review

References (136)

1. Breé chot C (1997) Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma. Hepatology 25: 772-774
2. Pawlotsky JM, GermanidisG, Frainais PO, BouvierM, Soulier A, PellerinM and Dhumeaux D (1999) Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J. Virol. 73: 6490-6499
3. Lohmann V, Korner F, Koch J, Herian U, Theilmann L and Bartenschlager R. (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113
4. Blight KJ, Kolykhalov AA and Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290: 1972-1974
5. Pietschmann T, Lohmann V, Rutter G, Kurpanek K and Bartenschlager R (2001) Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75: 1252-1264
6. Krieger N, Lohmann V and Bartenschlager R (2001) EnhancementofhepatitisC virus RNA replication by cell culture- adaptive mutations. J. Virol. 75: 4614-4624
7. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL and Kneteman NM (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7: 927-933
8. Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G, Rogiers X, Rogler CE, Gupta S, Will H, Greten H and Petersen J (2001) Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 334: 981-988
9. Ohashi K, Marion PL, Nakai H, Meuse L, Cullen JM, Bordier BB, Schwall R, Greenberg HB, Glenn JS and Kay MA. (2000) Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat. Med. 6: 327-331
10. Fend F, Kremer M and Quintanilla-Martinez L (2000) Laser capture microdissection: methodical aspects and applications with emphasis on immuno-laser capture microdissection. Pathobiology 68: 209-214
11. Zignego AL, Macchia D, Monti M, Thiers V, Mazzeti M, Foschi M, Maggi E, Romagnani S, Gentilini P and Bre chot C (1992) Infection of peripheral mononuclear blood cells by hepatitis C virus. J. Hepatol. 15: 382-386
12. Zignego AL, Ferri C, Monti M, LaCivita L, Giannini C, Careccia G, Giannelli F, Pasero G, Bombardieri S and Gentilini P (1995) Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Clin. Exp. Rheumatol. 13 (Suppl 13): S33-S37
13. Moldvay J, Deny P, Pol S, Bre chot C and Lamas E (1994) Detection of hepatitis Cvirus RNA in peripheral blood mononuclear cells of infected patients by in situ hybridization. Blood 83: 269-273.
14. Agnello V, Chung R and Kaplan L (1992) A role for hepaitits C virus infection in type II cryoglobulinemia. New Engl. J. Med. 327: 1490-1495
15. Zignego A and Bréchot C (1999) Extrahepatic manifestations of HCV infection: facts and controversies. J. Hepatol. 31: 1152-1154
16. Bronowicki JP, Loriot MA, Thiers V, Grignon Y, Zignego AL and Brechot C (1998) Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology 28: 211-218
17. Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud MA, Trepo C and Inchauspe G (1998) In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 91: 3841-3849
18. Shimizu YK, Igarashi H, Kanematu T, Fujiwara K, Wong DC, Purcell RH and Yoshikura H (1997) Sequence analysis of the Hepatitis C virus genome recovered fromserum, liver, and peripheral bloodmononuclear cells of infected chimpanzees. J. Virol. 71: 5769-5773
19. Morsica G, Tambussi G, SitiaG, NovatiR, LazzarinA, LopalcoL and MukengeS (1999) Replication of hepatitis C virus in B lymphocytes (CD19+). Blood 94: 1138-1139
20. Maggi F, Fornai C, Vatteroni ML, Giorgi M, Morrica A, Pistello M, Cammarota G, Marchi S, Ciccorossi P, Bionda A and Bendinelli M (1997) Differences in Hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma. J. Gen. Virol. 78: 1521-1525
21. Afonso AM, Jiang J, Penin F, Tareau C, Samuel D, Petit MA, Bismuth H, Dussaix E and Feray C (1999) Nonr and om distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. J. Virol. 73: 9213-9221
22. Loriot MA, Bronowicki JP, Lagorce D, Lakehal F, Barba G, Merget M, Vons C, Franco D, Belghiti J, Housset C and Bre chot C (1999) Permissivity of human biliary epithelial cells to infection by hepatitis C virus. Hepatology 29: 1587-1595
23. Bichr S, Rende-Fournier R, Vona G, Yamamoto AM, Depla E, Maertens G and Brechot C (2002) Detection of neutralizing antibodies to hepatitisCvirus using a biliary cell infection model. J. Gen. Virol. 83: 1673-1678.
24. Goodman ZD and Ishak KG (1995) Histopathology of HepatitisCvirus infection. Sem. Liver Dis. 15: 70-81
25. Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, Urdea M, Reynes M, Brechot C and Bismuth H (1994) Thecourse of hepatitisCvirus infection after liver transplantation. Hepatology 20: 1137-1143
26. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, David MF, Reynes M, Okamoto H, Bismuth H and Brechot C (1995) Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 108: 1088-1096
27. Zignego AL, Giannelli F, Marrocchi ME, Mazzocca A, Ferri C, Giannini C, Monti M, Caini P, Villa GL, Laffi G and Gentilini P (2000) T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 31: 474-479
28. Zignego A, Ferri C, Giannelli F, Giannini C, Marrocchi M, Monti M, Caini P, La Villa G, Laffi G and Gentilini P (2002) Prevalence of bcl-2 rearrangement in hepatitis Cvirus-relatedmixed cryoglobulinemia with or without complicating B cell lymphoma. Ann. Inter. Med. 137: 571-580.
29. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D and Rowe JM (2001) The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 97: 1555-1559
30. Heim MH, Moradpour D and Blum HE (1999) Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STATpathway. J. Virol. 73: 8469-8475
31. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F and Sato C (1995) Comparison of full-length sequences of interferon-sensitive and resistant hepatitis Cvirus 1b.Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 96: 224-230
32. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F and Sato C (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New Engl. J. Med. 334: 77-81
33. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR and Katze MG (1997) Evidence that hepatitisCvirus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230: 217-227
34. Gale Jr M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR and Katze MG (1998) Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18: 5208-5218
35. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Suzuki Y, Murashima N, Ikeda K and Kumada H (1997) Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25: 745-749
36. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F and Sato C (1997) Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 25: 750-753
37. Komatsu H, Fujisawa T, Inui A, Miyagawa Y and Onoue M (1997) Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitisc virus 1b infection. J. Med. Virol. 53: 361-365
38. Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, Pol S and Brechot C (1997) Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon a. Gastroenterology 113: 567-572
39. Rispeter K, Lu M, Zibert A, Wiese M, Mendes de Oliveira J and Roggendorf M (1999) A suggested extension of the HCV ISDR does not alter our former conclusionson its predictive value for IFN response. J. Hepatol. 30:1163-1164
40. Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, Lunel F, Eb F, Penin F and Wychowski C (1998) Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J. Gen. Virol. 79: 1373-1381
41. Polyak SJ, Mac Ardle S, Liu SL, Sullivan DG, Chung M, Hofgartner WT, Carithers RL, MacMahon B, Mullins JI, Corey L and Gretch DR (1998) Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J. Virol. 72: 4288-4296
42. Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO and Dhumeaux D (1998) Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations. J. Virol. 72: 2795-2805
43. Nakano I, Fukuda Y, Katano Y, Nakano S, Kumada T and Hayakawa T (1999) Why is the interferon sensitivity-determining region (ISDR) system useful in Japan? J. Hepatol. 30: 1014-1022
44. Paterson M, Laxton CD, Thomas HC, AckrillAM and FosterGR(1999)Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with the clinical response. Gastroenterology 117: 1187-1197
45. Song J, Fujii M, Wang F, Itoh M and Hotta H (1999) TheNS5Aprotein of hepatitis Cvirus partially inhibits the antiviral activity of interferon. J.Gen. Virol. 80: 879-886
46. Podevin P, Sabile A, Gajardo R, Delhem N, Abadie A, Lozach PY, Beretta L and Brechot C (2001) Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKRindependent manner. Hepatology 33: 1503-1511
47. Ide Y, Tanimoto A, Sasaguri Y and Padmanabhan R (1997) Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase A-a catalytic subunit. Gene 201: 151-158
48. Koch J and Bartenschlager R (1999) Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteinsNS3, NS4A, NS4B. J.Virol. 73: 7138-7146
49. Gale Jr M, Kwieciszewski B, Dossett M, Nakao H and Katze MG (1999) Antiapoptotic and Oncogenic Potentials of Hepatitis C Virus Are Linked to Interferon Resistance by Viral Repression of the PKR Protein Kinase. J. Virol. 73: 6506-6516
50. Pflugheber J, Fredericksen B, Sumpter Jr R, Wang C, Ware F, Sodora DL and Gale Jr M (2002) Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc. Natl. Acad. Sci. USA 99: 4650-4655
51. Francois C, Duverlie G, Rebouillat D, Khorsi H, Castelain S, Blum HE, Gatignol A, Wychowski C, Moradpour D and Meurs EF (2000) Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J. Virol. 74: 5587-5596
52. Fukuma T, Enomoto N, Marumo F and Sato C (1998) Mutations intheinterferonsensitivity determining region of hepatitisCvirus and transcriptionnal activity of the nonstructural region 5A protein. Hepatology 28: 1147-1153
53. Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G, Barber GN, Levy DE, Mukaida N and Gretch DR (2001) Hepatitis Cvirus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75: 6095-6106
54. Tan SL, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ and Katze MG (1999) NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/lig and -dependentmanner and perturbs mitogenic signaling. Proc.Natl. Acad. Sci. USA 96: 5533-5538
55. Gong G, Waris G, Tanveer R and Siddiqui A (2001) Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc. Natl. Acad. Sci. USA 98: 9599-9604
56. Taylor DR, Shi ST, Romano PR, Barber GN and Lai MM (1999) Inhibition of the interferon-inducible protein kinase PKR by HCVE2 protein. Science 285: 107-110
57. Delhem N, Sabile A, Gajardo R, Podevin P, Abadie A, Blaton M, Kremsdorf D, Beretta L and Brechot C (2001) Activation of the interferon-inducible protein kinase PKR by Hepatocellular carcinoma derived-Hepatitis Cvirus coreprotein. Oncogene 20: 5836-5845
58. Naganuma A, Nozaki A, Tanaka T, Sugiyama K, Takagi H, Mori M, Shimotohno K and Kato N (2000) Activation of the interferon-inducible 2'-5'-oligoadenylate synthetase gene by hepatitis C virus core protein. J. Virol. 74: 8744-8750
59. Brechot C, Jaffredo F, Lagorce D, Gerken G, Meyer zum Buschenfelde K, Papakonstontinou A, Hadziyannis S, Romeo R, Colombo M, Rodes J, Bruix J, Williams R and Naoumov N (1998) Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J. Hepatol. 29: 173-183
60. Colombo M and Romeo R (1994) Hepatitis C virus infection and hepatocellular carcinoma. InPrimary liver cancer:Etiological and progression factors.Bréchot C, ed. BocaRaton, Fl, USA: CRC Press
61. Bréchot C (1996) Hepatitis C virus: molecular biology and clinics. In Acute and chronic liver diseases.Molecular biology and clinics, Vol 9, Schmid R, BianchiL, Blum HE, Gerok W, Maier KP and Stalder GA, ed (Basel: Kluwer Academic) pp.7-27
62. Paterlini P and Bréchot C (1994) Hepatitis B virus and primary liver cancer in hepatitis B surface antigen-positive and negative patients. In Primary liver cancer: Etiological and progression factors. Bréchot C, ed (Paris: CRC Press) pp.167-190
63. DeMitri S, Poussin K, Baccarini P, Pontisso P, D'Errico A, Simon N, Grigioni W, Alberti A, Beaugrand M, Pisi E, Brechot C and Paterlini P (1995) HCVassociated liver cancer without cirrhosis. Lancet 345: 413-415
64. Paterlini P, Driss F, Pisi E, Franco D, Berthelot P and Bréchot C (1993) Persistence of hepatitis B and hepatitis Cviral genomes in primary liver cancers from HBsAg negative patients: a study of a low endemic area. Hepatology 17: 20-29
65. Tsuboi SO, Nagamori S, Miyazaki M, Mihara K, Fukaya K, Teruya K, Kosaka T, Tsuji T and Namba M (1996) Persistence of hepatitis c virus RNAin established human hepatocellular carcinoma cell lines. J. Med. Virol. 48: 133-140
66. Lai MM and Ware CF (2000) Hepatitis Cvirus core protein: possible roles in viral pathogenesis. Curr. Top. Microbiol. Immunol. 242: 117-134
67. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman M, Miyamura T and Bréchot C (1997) HepatitisCvirus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc. Natl. Acad. Sci. USA 94: 1200-1205
68. Yasui K, Wakita T, Tsukiyama-Kohara K, Funahashi SI, Ichikawa M, Kajita T, Moradpour D, Wands JR and Kohara M (1998) The native form and maturation process of hepatitis C virus core protein. J. Virol. 72: 6048-6055
69. Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C and Lai MM (1998) Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhancesTNF-induced apoptosis. J.Virol. 72: 3691-3697
70. You LR, Chen CM and Lee YHW (1999) Hepatitis Cvirus core protein enhances NF-kappaB signal pathway triggering by lymphotoxin-beta receptor lig and and tumor necrosis factor alpha. J. Virol. 73: 1672-1681
71. Owsianka AM and Patel AH (1999) Hepatitis Cvirus core protein interacts with a human DEAD box protein DDX3. Virology 257: 330-340
72. Hsieh TY, Matsumoto M, Chou HC, Schneider R, Hwang SB, Lee AS and Lai MM (1998) Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K. J. Biol. Chem. 273: 17651-17659
73. Shrivastava A, Manna SK, Ray R and Aggarwal BB (1998) Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. J. Virol. 72: 9722-9728
74. Giambartolomei S, Covone F, Levrero M and Balsano C (2001) Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis CVirus (HCV)core protein Oncogene 20:2606-2610
75. Fukuda K, Tsuchihara K, Hijikata M, Nishiguchi S, Kuroki T and Shimotohno K (2001) Hepatitis Cvirus core protein enhances the activation of the transcription factor, Elk1, in response to mitogenic stimuli. Hepatology 33: 159-165
76. Aoki H, Hayashi J, Moriyama M, Arakawa Y and Hino O (2000) HepatitisCvirus core protein interacts with 14-3-3 protein and activates thekinaseRaf-1. J.Virol. 74: 1736-1741
77. Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y and Hino O (2000) Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology 32: 958-961
78. Erhardt A, Hassan M, Heintges T and Haussinger D (2002) Hepatitis C Virus Core Protein Induces Cell Proliferation and Activates ERK, JNK, and p38 MAP Kinases Together with theMAPKinasePhosphataseMKP-1inaHepG2Tet-Off Cell Line. Virology 292: 272-284
79. Bergqvist A and Rice CM (2001) Transcriptional activation of the interleukin-2 promoter by hepatitis C virus core protein. J. Virol. 75: 772-781
80. Lee CH, Choi YH, Yang SH, Lee CW, Ha SJ and Sung YC (2001) Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages. Virology 279: 271-279
81. Ray R, Steele R and Meyer Kea (1998) Hepatitis Cvirus core protein represses p21 WAF1/Cip1/Sid1 promoter activity. Gene 208: 331-336
82. Ray RB, Steele R, Meyer K and Ray R (1997) Transcriptional repression of p53 promoter by hepatitis C virus core protein. J. Biol. Chem. 272: 10983-10986
83. Jung EY, Lee MN, Yang HY, Yu D and Jang KL (2001) The repressive activity of hepatitis C virus core protein on the transcription of p21(waf1) is regulated by protein kinase A-mediated phosphorylation. Virus Res. 79: 109-115
84. Suzuki R, Matsuura Y, Suzuki T, ando A, Chiba J, Harada S, Saito I and Miyamura T (1995) Nuclear localisation of the truncated hepatitis C virus core protein with its hydrophobic C-terminus deleted. J. Gen. Virol. 76: 53-61
85. Rüster B, Zeuzem S and Roth WK (1996) HepatitisCvirus sequences encoding truncated core proteins detected in a hepatocellular carcinoma. Bioch. Bioph. Res. Comm. 219: 911-915
86. Horie C, Iwahana H, Horie T, Shimizu I, Yoshimoto K, Ishikawa T, Nagai Y and Kakumu S (1996) Detection of different quasispecies of hepatitis C virus core region in cancerous and non-cancerous lesions. Bioch. Bioph. Res. Comm. 218: 674-681
87. Chang S, Hu T and Hsieh TS (1998) Analysis of a core domain in Drosophila DNA topoisomerase II. Targeting of an antitumor agent ICRF-159. J. Biol. Chem. 273: 19822-19828
88. Tsuchihara K, Hijikata M, Fukuda K, Kuroki T, Yamamoto N and Shimotohno K (1999) Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology 258: 100-107
89. Ray RB, Lagging LM, Meyer K and Ray R (1996) Hepatitis C virus core protein cooperates with rasand transforms primary rat embryo fibroblasts to tumorigenic phenotype. J. Virol. 70: 4438-4443
90. Jin DY, Wang HL, Zhou Y, Chun AC, Kibler KV, Hou YD, Kung H and Jeang KT (2000) Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. EMBO J. 19: 729-740
91. Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K and Miyamura T (2002) Interaction of hepatitisCvirus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 35: 937-946
92. Cho J, Baek W, Yang S, Chang J, Sung YC and Suh M (2001) HCV core protein modulatesRb pathway through pRβ down-regulation and E2F-1 up-regulation. Biochim. Biophys. Acta 1538: 59-66
93. Cho JW, Baek WK, Suh SI, Yang SH, Chang J, Sung YC and Suh MH (2001) Hepatitis C virus core protein promotes cell proliferation through the upregulation of cyclin E expression levels. Liver 21: 137-142
94. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T and Koike K (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4: 1065-1070
95. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA and Lemon SM (2002) Steatosis and liver cancer intransgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122: 352-365
96. Pasquinelli C, Shoenberger JM, Chung J, Chang KM, Guidotti LG, Selby M, Berger K, Lesniewski R, Houghton M and Chisari FV (1997) Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 25: 719-727
97. Moriya K, Todoroki T, Tsutsumi T, Fujie H, Shintani Y, Miyoshi H, Ishibashi K, Takayama T, Makuuchi M, Watanabe K, Miyamura T, Kimura S and Koike K (2001) Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. Biochem. Biophys. Res. Commun. 281: 1207-1212
98. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM and Weinman SA (2002) Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122: 366-375
99. Kalkeri G, Khalap N, Garry RF, Fermin CD and Dash S (2001) Hepatitis C virus protein expression induces apoptosis in HepG2 cells. Virology 282: 26-37
100. Ruggieri A, Harada T, Matsuura Y and Miyamura T (1997) Sensitization to Fasmediated apoptosis by hepatitis C virus core protein. Virology 229: 68-76
101. Ray R, Ghosh A, Meyer K and Ray R (1999) Functional analysis of a transrepressor domain in the hepatitisCvirus core protein. VirusRes. 59: 211-217
102. Ray R, Meyer K, Steele R, Shrivastava A, Aggarwal B and Ray R (1998) Inhibition of tumor necrosis factor (TNF-a)-mediated apoptosis by hepatitis C virus core protein. J. Biol. Chem. 273: 2256-2259
103. Marusawa H, Hijikata M, Chiba T and Shimotohno K (1999) Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J. Virol. 73: 4713-4720
104. Zhu N, Ware CF and Lai MM (2001) Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppressesTRADDsignaling of tumor necrosis factor receptor. Virology 283: 178-187
105. Dumoulin FL, vsn dem Bussche A, Sohne J, Sauerbruch T and Spengler U (1999) Hepatitis C virus core protein does not inhibit apoptosis in human hepatoma cells. European. J. Clin. Invest. 29: 940-946
106. Giannini C, Caini P, Giannelli F, Fontana F, Kremsdorf D, Brechot C and Zignego AL (2002) Hepatitis C virus core protein does not significantly modify main proliferative and apoptosis pathways. J. Gen. Virol. 83: 1665-1671.
107. Machida K, Tsukiyama-Kohara K, Seike E, Tone S, Shibasaki F, Shimizu M, Takahashi H, Hayashi Y, Funata N, Taya C, Yonekawa H and Kohara M (2001) Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenicmice inducedto express hepatitisCviral proteins. J. Biol.Chem.276: 12140-12146
108. Sakamuro D, Furukawa T and Takegami T (1995) Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J. Virol. 69: 3893-3896
109. Zemel R, Gerechet S, Greif H, Bachmatove L, Birk Y, Golan-Goldhirsh A, Kunin M, Berdichevsky Y, Benhar I and Tur-Kaspa R (2001) Cell transformation induced by hepatitis C virus NS3 serine protease. J. Viral. Hepat. 8: 96-102
110. Borowski P, Heiland M, Feucht H and Laufs R (1999) Characterisation of nonstructural protein 3 of hepatitis C virus asmodulator of protein phosphorylation mediated by PKA and PKC: evidences for action on the level of substrate and enzyme. Arch. Virol. 144: 687-701
111. Kwun HJ, Jung EY, Ahn JY, Lee MN and Jang KL (2001) p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J. Gen. Virol. 82: 2235-2241
112. Bureau C, Bernad J, Chaouche N, Orfila C, Beraud M, Gonindard C, Alric L, Vinel JP and PipyB (2001) Nonstructural 3protein of hepatitisCvirus triggersan oxidative burst in human monocytes via activation of NADPH oxidase. J. Biol. Chem. 276: 23077-23083
113. Ghosh AK, Steele R, Meyer K, Ray R and Ray RB (1999) HepatitisCvirusNS5A proteinmodulates cell cycle regulatory genes and promotes cell growth. J.Gen. Virol. 80: 1179-1183
114. Polyak SJ, Paschal DM, McArdle S, Gale Jr MJ, Moradpour D and Gretch DR (1999) Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 29: 1262-1271
115. Kaufman RJ (1999) Double-str and ed RNA-activated protein kinase mediates virus-inducedapoptosis:anewrole foranoldactor [comment]. Proc.Natl.Acad. Sci. USA 96: 11693-11695
116. Arima N, Kao CY, Licht T, Padmanabhan R and Sasaguri Y (2001) Modulation of cell growth by the hepatitisCvirus nonstructural protein NS5A. J.Biol.Chem. 276: 12675-12684
117. Majumder M, Ghosh AK, Steele R, Ray R and Ray RB (2001) Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J. Virol. 75: 1401-1407
118. Ghosh AK, Majumder M, Steele R, Yaciuk P, Chrivia J, Ray R and Ray RB (2000) Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP. J. Biol. Chem. 275: 7184-7188
119. Bréchot C (1998) Molecularmechanisms of hepatitis B and Cviruses related to liver carcinogenesis. Hepato-gastroenterology 45: 1189-1196
120. Nousbaum J, Pol S, Nalpas B, Landais P, Berthelot P and Bréchot C (1995) Hepatitis C virus type 1b (II) infection in France and Italy. Ann. Inter. Med. 122: 161-168
121. Gane EJ, Naoumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, Lau JYN and Williams R (1996) Alongitudinal analysisofhepatitisCvirus replication following liver transplantation. Gastroenterology 110: 167-177
122. Bruno S, Silini S, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Largui A, Cerino A, Podda M and Mondelli M (1997) Hepatitis CVirus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 25: 754-758.
123. Yamauchi M, Nakahara M, Hisato N, Kazuhiko S, Junnichi H and Toda G (1994) Different prevalence of hepatocellular carcinoma between patients with liver cirrhosis due to genotype II and III of hepatitis C virus. Inter. Hepatol. Comm. 2: 328-332
124. Thomssen R, Bonk S and Thiele A (1993). Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med. Microbiol. Immunol. (Berl) 182: 329-334
125. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG and Uy A (1992) Association of hepatitis C virus in human sera with beta-lipoprotein. Med. Microbiol. Immunol. 181: 293-300
126. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S and Thomssen R (1999) Low density lipoprotein receptor as a c and idate receptor for hepatitis C virus. J. Med. Virol. 57: 223-229
127. Agnello V, Abel G, Elfahal M, Knight GB and Zhang QX (1999) HepatitisCvirus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 96: 12766-12771
128. Czaja AJ, Carpenter HA, Santrach PJ and Moore SB (1998) Host- and diseasespecific factors affecting steatosis in chronic hepatitis C. J. Hepatol. 29: 198-206
129. Lette ron P, Fromenty B, Terris B, Degott C and Pessayre D (1996) Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation inmice. J.Hepatol. 24: 200-208
130. Sabile A, Perlemuter G, Bonbo F, Kohara K, Demaugre F, Matsuura Y, Bréchot C and Barba G (1999) HepatitisCvirus core protein binds to apolipoprotein A11 and s its secretion is modulated by fibrates. Hepatology 4: 1064-1076
131. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR and Lai MM (2002) Hepatitis C Virus NS5A Colocalizes with the Core Protein on Lipid Droplets and Interacts with Apolipoproteins. Virology 292: 198-210
132. Hope RG, Murphy DJ and McLauchlan J (2002) The domains required to direct core proteins of hepatitisCvirus and GB virus-B to lipid droplets share common features with plant oleosin proteins. J. Biol. Chem. 277: 4261-4270
133. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chretien Y, Koike K, Pessayre D, Chapman J, Barba G and Brechot C (2002) Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 16: 185-194
134. Maillard P, Krawczynski K, Nitkiewicz J, Bronnert C, Sidorkiewicz M, Gounon P, Dubuisson J, Faure G, Crainic R and Budkowska A (2001) Nonenveloped nucleocapsids of hepatitis c virus in the serum of infected patients. J. Virol. 75: 8240-8250
135. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ and Hahn YS (2000) Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J. Clin. Invest. 106: 1239-1249
136. Rubbia-Brandt L, Giostra E, Quadri R, Malé P, Mentha G, Sparhr J, Zarski J, Borisch B, Hadengue A and Negro F (1999) Evidence that liver steatosis is virally-mediated in a subset of patients infected by hepatitis C virus (HCV) genotype 3. J. Hepatol. 30 (Suppl 1): 133